Apexion Health Women's Testosterone Therapy injection vial
HORMONEWOMEN'S HEALTH

MONTHLY SUPPLY · INJECTION

WOMEN'S TESTOSTERONE THERAPY

TREATMENT

Injectable testosterone for comprehensive female hormone optimization

SUPPORT

Injectable testosterone cypionate at low female-appropriate doses provides stable, consistent androgen delivery for women seeking comprehensive hormone optimization — used when topical gel is insufficient or when precise serum titration is preferred.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — HORMONE

INJECTABLE TESTOSTERONE. PRECISION ANDROGEN OPTIMIZATION FOR WOMEN.

Injectable testosterone cypionate in low, female-appropriate doses provides more consistent and measurable serum levels compared to topical application, where skin absorption can vary. Administered weekly or biweekly at doses of 5–20 mg (compared to 100–200 mg for male TRT), injectable therapy is used when gel formulations provide insufficient response, when monitoring requires tighter pharmacokinetic control, or when a patient and her provider prefer the predictability of injections. Physician monitoring with serial total and free testosterone, SHBG, hematocrit, and symptom tracking is required.

Clinical Benefits

WOMEN'S TESTOSTERONE THERAPY SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    DELIVERS CONSISTENT SERUM TESTOSTERONE LEVELS VIA INJECTION

  2. 02.

    SUPERIOR PHARMACOKINETIC PREDICTABILITY VERSUS TOPICAL GEL

  3. 03.

    SUPPORTS SEXUAL DESIRE, ENERGY, AND LEAN MUSCLE IN WOMEN

  4. 04.

    FEMALE-CALIBRATED DOSE — SIGNIFICANTLY LOWER THAN MALE TRT

  5. 05.

    WEEKLY OR BIWEEKLY INJECTION SCHEDULE

  6. 06.

    PHYSICIAN-MONITORED WITH COMPREHENSIVE HORMONE PANELS

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

Target Free T Restoration

Transdermal Cream/gel for stable levels80%
Libido Response ~60% report meaningful improvement60%
Dose Titration Start low, escalate slowly55%

Davis et al., Lancet 2019; IMS Global Consensus 2019

02 — Hormone Panel

Dosing & Safety Parameters

MarkerWithoutWith Treatment
Total T Targetng/dL
12
25–50+13–38
Free T Targetpg/mL
1.5
4–8+2.5–6.5
SHBGnmol/L
80
60−20
Androgenic EffectsRate
0
~10–20%10–20%

Target: upper premenopausal free T range

Unlike men’s TRT, target free T in upper premenopausal range (~4–8 pg/mL). SHBG often elevated, binding T. Transdermal creams (0.5–2 mg/day) provide most physiologic delivery.

Davis et al., Lancet 2019; IMS Global Consensus 2019; NAMS 2022

03 — Protocol

Women’s T Prescribing Protocol

WorkupPre-treatment
  • Total T (LC-MS/MS)
  • Free T (equilibrium dialysis)
  • SHBG, DHEA-S
  • Lipids, LFTs, mammogram
InitiationMonths 1–3
  • Transdermal cream 0.5–1 mg/day
  • T levels at 4–6 weeks (trough)
  • Titrate to upper premenopausal range
MaintenanceMonth 4+
  • Maintain lowest effective dose
  • T, lipids, LFTs q6 months
  • Androgenic side effect screening

Compounded creams — no FDA-approved female T in US

All female T prescribing is off-label or compounded. Apply to rotating sites (inner thigh, buttock, lower abdomen). Avoid transfer to partners/children. Long-term safety data >3 years limited.

All protocols physician-supervised and adjusted per individual labs.